I alluded to these three graphs in a presentation today, so here they are. The first one shows the recent uptick in drugs being developed at all stages; the second shows how the number of new drugs in post-clinical stage is abysmal; and the the third shows the flat-line in new molecular entities (NMEs). (The first two graphs are courtesy of PharmaProjects, while the third is from Parexel.)
Related posts: